The nucleotides and oligonucleotides comprising at least one of said nucleotides can be used in therapy (such as antisense or antigene therapy) and in methods for synthesising polynucleotides (e.g. as a primer).

The present invention also provides a method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefit in the treatment of myeloma.

All four drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

angle-left The MUHC teams up with LSU Health New Orleans to advance Usher Syndrome antisense therapy research

The modified nucleotides and nucleotides are assembled to larger oligonucleotides and oligonucleosides, which, for example, may be used for diagnostics of polymorphisms and for antisense therapy of various conditions.

The monomers and oligomers of the present invention can be used for antisense therapy inhibiting the expression of disease-inducing genes, hybridization of gene cloning and reagents for diagnosis.

Home / News / News / The MUHC teams up with LSU Health New Orleans to advance Usher Syndrome antisense therapy research

Oligonucleotides of specific gene sequences that include one or more 3', 5'-linking-(carboran-1-yl)phosphonate moieties can also be used in antisense therapy in the selective modification of gene expression.